Pfizer asks FDA to approve omicron-specific booster shot
Aug 22, 2022
The drug company says that its new mRNA vaccine produces an immune response against the BA.4 and BA.5 omicron subvariants.
NIH spending nearly $470 million on ‘long-haul COVID’ study
Sep 16, 2021
Goal is to uncover why some people have prolonged symptoms or develop new or returning symptoms after recovering from COVID-19
COVID-19 rapid test makers struggling to meet demand
Jan 21, 2022
However, government’s order for the free test kits is in addition to existing supply and does not interfere with existing orders
Burden of persistent symptoms high after COVID-19 infection
May 24, 2022
– A high burden of persistent symptoms is observed in persons after COVID-19, but no specific causes of symptoms of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)...
Long COVID may qualify as a disability: Biden
Jul 27, 2021
Some recovered COVID-19 patients have lasting problems such as fatigue, brain fog, joint pain, fever, and double vision
Risk factors ID’d for conversion from RIS to multiple sclerosis
Oct 18, 2021
For radiologically isolated syndrome, younger age, spinal cord lesions, gadolinium-enhancing lesions at time of index scan tied to increased risk
Guidelines developed for exercise at altitude in CVD patients
Sep 14, 2021
Pretrip planning should consider locations and duration of altitude exposure, hydration and medication use, emergency planning
More clinical benefits of molnupiravir ID’d in COVID-19
Jun 07, 2022
New benefits for certain COVID-19 patients, including reduced need for respiratory intervention, have been found for Merck’s COVID-19 pill molnupiravir.
Most US adults with type 2 diabetes meet criteria for GLP-RAs, SGLT2is
Feb 28, 2023
More than 82% US adults with type 2 diabetes meet the criteria to be prescribed the drugs, yet only 9% use either of them.
Pfizer says final data show COVID-19 pill stays strong against severe illness
Dec 14, 2021
Latest results show that drug cuts hospitalizations, deaths by nearly 90 percent when taken within three to five days of the start of symptoms